Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Dec;18(12):CS113-6.
doi: 10.12659/msm.883620.

Vertical genotype 1 HCV infection treated successfully in the second year of life: a case report

Małgorzata Pawłowska  1 , Waldemar Halota, Ewa Smukalska
Affiliations
Case Reports

Vertical genotype 1 HCV infection treated successfully in the second year of life: a case report

Małgorzata Pawłowska et al. Med Sci Monit. 2012 Dec.

Abstract

Background: Perinatal HCV transmission appears to be an important cause of HCV in children. Treatment of chronic hepatitis C in young children is controversial because of spontaneous HCV clearance and possible adverse events.

Case report: Vertical HCV genotype 1 infection was diagnosed in a 3-month-old infant. In the subsequent clinical examination we still observed hepatomegaly, fluctuations of ALT, AST and GGT activity, with the highest values 2206 U/L, 1319 U/L, and 297 U/L, respectively. In qPCR, HCV RNA was >700.000 IU/ml. In the 42nd week of observation, liver biopsy was performed with Grade 1 grading and Grade 1 staging. At age 12 months, interferon-alpha2b (1.5 MU 3 times a week) and ribavirin (2×80 mg daily) were administered for 48 weeks. At the beginning of the treatment we observed fever after IFN injection. In the 12th week of therapy, HCV RNA disappeared followed by SVR, and it was sustained for 6 years. To our knowledge, this is the first report of a pediatric (1-year-old) patient treated with combined IFN alpha-2b and ribavirin therapy.

Conclusions: This case report confirms the possibility of successful anti-HCV treatment in a young child, with 6-year sustained virological response without significant adverse events.

PubMed Disclaimer

References

    1. Pawłowska M, Halota W. Mother-to-child HBV and HCV transmission. Med Sci Rev Hepatology. 2009;9:54–56.
    1. Bevilacqua E, Fabris A, Floreano P, et al. Genetic factors in mother-to-child transmission of HCV infection. Virology. 2009;390(1):64–70. - PubMed
    1. Azzari C, Moriondo M, Indolfi G, et al. Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. J Med Virol. 2008;80(1):65–71. - PubMed
    1. Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period – are they opportunities for treatment? J Viral Hepat. 2011;18:229–36. - PubMed
    1. Yeung LT, To T, King SM, et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat. 2007;14(11):797–805. - PubMed

Publication types

Substances